NCT00146588 - Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions

Breast CancerStage I Breast CancerStage II Breast CancerStage IIIA Breast Cancer

Interventions

DRUG

Cyclophosphamide

Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.

DRUG

Epirubicin

Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.

DRUG

Capecitabine

Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.

Trial Locations (2)

Massachusetts General Hospital, Boston

Dana-Farber Cancer Center, Boston